Bruker (BRKR) Stock News

Bruker Corporation (BRKR) announced its participation in the upcoming Jefferies Global Healthcare Conference in New York City. The company's senior leadership will engage in a fireside chat presentation on Wednesday, June 4th, 2025, at 5:30 PM Eastern Time. Investors can access a live audio webcast of the presentation through Bruker's Investor Relations website at https://ir.bruker.com. The presentation recording will be available in the Events & Presentations section for 30 days following the event.

Bruker Corporation (BRKR) has launched the timsOmni™ mass spectrometer, a revolutionary system that enables unprecedented protein analysis capabilities. The device combines timsTOF technology with novel Omnitrap functionality, offering high-speed, high-sensitivity protein analysis and deep sequence coverage. Key features include multimodal electron and collision-induced ion fragmentation, precise electron energy control, and collision-induced unfolding. The system is supported by OmniScape™ software, which uses machine learning for advanced protein analysis. The timsOmni is particularly valuable for analyzing proteoforms, post-translational modifications, and complex biomolecules, making it essential for disease research, biologics development, and bioprocessing quality control. Notable applications include mapping histone modifications, analyzing glycosylation, and sequencing therapeutic antibodies.

Bruker Corporation (BRKR) has unveiled the timsMetabo, a cutting-edge 4D-Metabolomics mass spectrometer at the 73rd ASMS Conference. This breakthrough system features novel TIMS Mobility Range Enhancement (MoRE) technology and delivers exceptional sensitivity and separation power for small molecule analysis. The timsMetabo enables the creation of a 'digital metabolome archive' for each sample, utilizing trapped ion mobility separation technology and time-focusing capabilities. Key innovations include the dual-stage TIMS-MX ion funnel, high-precision quadrupole, and Athena Ion Processor (AIP), allowing for improved isomer resolution and MS/MS acquisition rates up to 300 Hz. The system supports both HESI and CSI ion sources and is complemented by the new QSee quality control suite with cloud-based TwinScape software for automated performance monitoring.

Bruker Corporation (BRKR) has launched the MOVE-T, an advanced liquid dairy analyzer utilizing Fourier Transform Near-Infrared (FT-NIR) technology. The system is designed for analyzing raw milk and other liquid dairy products, featuring a wear-free quartz cell for enhanced sensitivity and transferability. The MOVE-T complies with ISO 21543 (IDF 201) standards and is specifically tailored for the dairy industry and sectors processing liquid dairy products or plant-based drinks. GOLDSTEIG Cheese Factories has already implemented the system, praising its compact design, workflow integration, and method transferability. This launch completes Bruker's portfolio of dairy FT-NIR analyzers for laboratory and process control applications.

Bruker Corporation (NASDAQ: BRKR) has announced a quarterly cash dividend payment approved by its Board of Directors. The company will distribute $0.05 per share to stockholders. The dividend will be paid on June 27, 2025, to shareholders of record as of June 16, 2025.

Bruker Corporation (BRKR) has announced a global settlement with 10x Genomics to resolve their ongoing patent disputes. The settlement includes global patent cross-license agreements between both companies and will result in the dismissal of all pending lawsuits and administrative proceedings in multiple countries, including the United States, Germany, and before the European Unified Patent Court.

According to Mark R. Munch, Ph.D., President of the Bruker Nano Group, this resolution ensures that the scientific community can continue their research using Bruker's CosMx® and GeoMx® spatial biology platforms without concerns about litigation interference, particularly in fields such as oncology and neurobiology.

Bruker Corporation (BRKR) reported Q1 2025 financial results with revenues of $801.4 million, showing an 11.0% year-over-year increase. The company's Bruker Scientific Instruments (BSI) segment demonstrated strong performance with 5.1% organic revenue growth, while Q1 2025 GAAP diluted EPS was $0.11 and non-GAAP diluted EPS was $0.47, down 11.3% year-over-year.

Due to academic market and tariff challenges, Bruker has revised its FY 2025 guidance, now expecting revenues between $3.48 to $3.55 billion (3.5% to 5.5% growth) and non-GAAP EPS of $2.40 to $2.48 (0% to 3% growth). The company plans to implement cost and pricing initiatives, along with supply network re-engineering, to mitigate more than half of the new headwinds in 2025.

Bruker (BRKR) announced major advancements in spatial biology and multiomics research at AACR 2025. Key developments include:

• CosMx 2.0 upgrade offering 2X increase in RNA detection efficiency
• New same-slide multiomics feature analyzing whole transcriptome (~19,000 targets) and immuno-oncology proteins (up to 76 proteins)
• Introduction of nCounter Platform with multiomic capabilities for simultaneous RNA and protein analysis

The company will begin taking advance orders for CosMx Whole Transcriptome (WTX) assay in May, with commercial shipments in summer. The nCounter Multiomics with Immune Pathways Protein panel and Tumor Signaling Protein panel will be commercially available in second half of 2025.

Bruker (Nasdaq: BRKR) announced the launch of Beacon Discovery™ Optofluidic System, a new benchtop system for live single-cell functional analysis, at the AACR Annual Meeting 2025. The system features Bruker's proprietary Opto-Electrical Positioning technology and OptoSelect™ microfluidic chips.

The compact Beacon Discovery complements existing premium Beacon® platforms with a lower cost of ownership and reduced running costs. It offers precise single-cell isolation, control, and analysis capabilities using machine learning automation. The system enables multi-parameter temporal analysis over extended periods, combining live-cell imaging with sequential assays.

Targeting academic and biotech laboratories, Beacon Discovery focuses on applications in immuno-oncology, infectious diseases, autoimmune disorders, and immune profiling. Commercial shipments are expected later in 2025, with pre-orders now available.